

Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease

Information for the public

Published: 28 June 2017

www.nice.org.uk

Everolimus (Afinitor) and sunitinib (Sutent) are available on the NHS as possible treatments for some types of neuroendocrine tumours in adults if:

- the tumour is unresectable (cannot be completely removed by surgery) or metastatic (it has spread) and
- the disease is getting worse.

Everolimus is for treating pancreatic, gastrointestinal or lung neuroendocrine tumours and sunitinib is for treating pancreatic neuroendocrine tumours.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

[NHS Choices](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Cancer Research UK Patient Information](#) (previously CancerHelp UK), 0808 800 4040
- [Macmillan](#), 0808 808 0000
- [Neuroendocrine Cancer UK](#), 0800 434 6476 or 01926 883487.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2561-2